

# A Qualitative/Quantitative LC-QTOF-MS Assay for Forensic Drug Screening in Urine - Feasibility Study and Basic Method Validation

Laura M. Huppertz<sup>1</sup>, Karin Wendt<sup>2</sup>, Michaela Schmidt<sup>1</sup>, Ronja Peter<sup>1</sup>, Franziska Ehrhardt<sup>1</sup>, Carsten Baessmann<sup>2</sup>, Volker Auwärter<sup>1</sup>

<sup>1</sup>Institute of Forensic Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; <sup>2</sup>Bruker Daltonik GmbH, Bremen, Germany



Institute of Forensic Medicine  
Forensic Toxicology

## OBJECTIVES

- Comprehensive screening of forensic compounds in urine using LC-QTOF-MS
- Basic validation according to requirements for use in forensic routine casework
- Quantitative performance equivalent to QqQ

## INTRODUCTION

Full scan based screening methods using LC-QTOF-MS are a valuable tool for forensic analysis due to the possibility of qualitative/quantitative and retrospective data evaluation in a single run. In this study a previously developed LC-QTOF-MS screening workflow was validated for qualitative and quantitative analysis of drugs and drugs of abuse in human urine. To assess the methods' limitations regarding its' applicability to urine screening in post-mortem toxicology, workplace drug testing, drug facilitated crime (DFC), and intoxication cases as well as to prove that cut-off values for sobriety and fitness-to-drive testing are met, a basic validation including limits of detection, limits of quantitation, linearity, accuracy, selectivity, and precision was carried out.

## METHODS I

### Compounds of Interest


For this evaluation 93 of the most common drugs and drugs of abuse and their metabolites detected in routine case work of our institute were chosen.

6-Monoacetylmorphine (MAM)	Desmethyldoxepin	Nordazepam
7-Aminoclonazepam	Doxepin	O-Desmethylenlafaxine
7-Aminoflunitrazepam	Opipramol	Paracetamol (Acetaminophen)
alpha-Hydroxymidazolam	Egonine methyl ester	Pregabalin
Amiripryline	Flubromazepam	Quetiapine
Amphetamine	Galapentin	Remifentanyl
Atomoxetine	Ketamine	Risperidon
Bromazepam	MDEA	Triazolam
Citalopram	Midazolam	Zolpidem
Clonipramine	Mirtazapine	
Cocaine	Norclomipramine	
Carbamazepine	Melperone	Ritalinic acid
Clozapepam	Methadone	Temazepam
Cocacethylen	Methylphenidate	Tilidine
Desipramine	Morphine	Trazodone
Diphenhydramine	Norfentanyl	Tripropamine
Fentanyl	Nortridine	Venlafaxine
Flunitrazepam	Nortriptylin	Etizolam
Haloperidol	Oxazepam	
Levetiracetam	Oxycodone	
MDA	Pirritamide	
MDMA	Promazine	
9-Hydroxyrisperidone (Paliperidone)	EDOP	O-Desmethyldramadol
Alprazolam	Fluoxetine	Olanzapine
Amisulpride	Lamotrigine	Pethidine
Benzoylcocaine	Lorazepam	Promethazine
Buprenorphine	mCOP	Sertraline
Carbamazepine-epoxide	Methamphetamine	Sufentanil
Clozapine	Metoclopramide	THC-COOH
Cocaine	Norbuprenorphine	Tramadol
Diazepam	Nortalcopram	Zopiclone
Dihydrocodeine	Nortrimipramine (Imipramine)	

## METHODS II

### Sample Preparation

Ninety three substances of forensic relevance were spiked into ten different urine samples at the concentrations 1.0, 5.0, 10, and 50 ng/ml.




Separation was performed on a Bruker Intensity Solo C18 column using a 14 min gradient elution. The MS (Bruker impact II) was operated in positive electrospray ionization mode generating a full scan and broad band CID spectra (bbCID) using collision energy spread (24 - 36 eV).

UHPLC:	Bruker Elite UHPLC
Column:	Bruker Intensity Solo 1.8 C18-2, 2.1*100 mm and pre-column
Mobile phase A:	H <sub>2</sub> O/MeOH 99/1, 5 mM NH <sub>4</sub> formate / 0.01% HCOOH
Mobile phase B:	MeOH, 5 mM NH <sub>4</sub> formate / 0.01% HCOOH
Gradient:	multistep gradient 5 - 99.9% in 15 min (20 min cycle)
Flow rate:	flow gradient 0.2 - 0.48 ml/min,
Injection vol.:	2 µl
Column temp.:	40°C
MS:	Bruker impact II QTOF mass spectrometer
Ionization:	ESI(+), 2,500V
Scan range:	m/z 30 - 1000
Full scan rapidly alternating TOF MS (4eV) with bbCID (30eV +/- 6V) @ 2Hz	

### Data Analysis

Data evaluation was performed with TASQ 1.4 software using the TargetScreener HR 3.0 accurate masse database containing mass spectrometric and chromatographic information of 2184 drugs, drugs of abuse, new psychoactive substances (NPS) metabolites, and pesticides.



## RESULTS

### Limits of Detection (LOD) and Selectivity

LOD was set to the concentration at which a substance was detected in 95% of all measurements (n = 40, due to duplicate determination) according to the identification criteria on the right.

### Identification Criteria

- retention time  $\pm 0.3$  min
- signal to noise ratio  $> 3:1$  for all ions
- $[M+nH]^+$  and  $[M+nH+1]^+$  detected (MS)
- at least two qualifier ions with minimum one being a true fragment of the molecular ion (bbCID)

Identification at the lowest concentration (c = 1.0 ng/ml) was achieved for 60 % of the tested compounds. Only five compounds (paracetamol, THC-COOH, norclomipramine, piritramid, and levetiracetam) could not be detected in all samples at the investigated concentrations. This is probably due to matrix effects and/or low ionization yields.

Except THC-COOH and ethylglucuronide, most substances with legal cut-offs according to German regulations for abstinence screening in fitness-to-drive assessment (CTU3 criteria), were detected well below the respective requested cut-off concentrations.

Typical 'date rape drugs' like flunitrazepam, doxylamine, and diphenhydramine showed LODs sufficient for detection of a recent uptake of these drugs.

Designer benzodiazepines and fentanyl derivatives were detected with extraordinarily high sensitivity.


### Quantitative Results

The linear dynamic ranges were four magnitudes or greater. LOQ was set to the lowest LOD.


The precision ranged from 8 % to 30 %. Overall accuracy met the criteria for bioanalytical method validation according to forensic guidelines.

The method showed good selectivity/specificity fulfilling the requirements stated in the respective guidelines.

Compounds	CTU3 LOD	LC-QTOF LOD
<b>Amphetamines:</b>		
Amphetamine	50 ng/ml	5.0 ng/ml
MDA	50 ng/ml	10 ng/ml
MDMA	50 ng/ml	10 ng/ml
<b>Methamphetamine</b>	50 ng/ml	50 ng/ml
<b>Cocaine:</b>		
Benzoylcocaine	30 ng/ml	10 ng/ml
Cocaine	30 ng/ml	5.0 ng/ml
<b>Opiates:</b>		
Codine	25 ng/ml	10 ng/ml
Dihydrocodeine	25 ng/ml	5.0 ng/ml
Morphine	25 ng/ml	5.0 ng/ml
<b>Methadone:</b>		
EDOP	50 ng/ml	1.0 ng/ml
Methadone	50 ng/ml	1.0 ng/ml
<b>Benzodiazepines:</b>		
Diazepam	50 ng/ml	1.0 ng/ml
Nordazepam	50 ng/ml	1.0 ng/ml
Oxazepam	50 ng/ml	1.0 ng/ml
Alprazolam	50 ng/ml	1.0 ng/ml
Hydroxylalprazolam	50 ng/ml	not investigated
Bromazepam	50 ng/ml	1.0 ng/ml
Flunitrazepam	50 ng/ml	1.0 ng/ml
7-Aminoflunitrazepam	50 ng/ml	50 ng/ml
Lorazepam	50 ng/ml	1.0 ng/ml
<b>Canabinoids:</b>		
THC-COOH	10 ng/ml	> 50 ng/ml
<b>Alcohol:</b>		
Ethylglucuronide	100 ng/ml	not investigated



### Limits of Detection evaluated in 10 different urine matrices on two LC-QTOF systems



Not detected @ tested levels  
Paracetamol (Acetaminophen)  
Levetiracetam  
Piritramid  
Nortalcopram  
THC-COOH

## CONCLUSION

In this project, the analytical possibilities and limitations of an LC-QTOF approach for screening urine samples were evaluated using 93 forensic compounds with high prevalence in our everyday case work.

For a screening method, selectivity and LODs are the most important analytical parameters. Evaluated LODs were comparable with those of standard triple quadrupole (QqQ) methods for the majority of compounds investigated. Although, high end QqQ may reach lower LODs, considering the high number of analytes due to full scan analysis, LC-QTOF is a valuable tool for toxicological analysis and the presented LODs are sufficient for most analytical problems in everyday case work.

Given the high frequency of new psychoactive substances emerging on web-based drug markets and related fatalities, this is of particular interest to the forensic field due to the possibility of retrospective data evaluation.

Extrapolating the here presented urine analysis results, application to blood and hair samples seems promising and will be evaluated in a subsequent study.

## ACKNOWLEDGEMENTS

Parts of this work have been funded by the "Deutsche Forschungsgemeinschaft" (DFG; German Research Foundation, INST 380/92-1 FUGG)

